Skip to main content
. 2019 Mar 24;57(1):231–237. doi: 10.1080/13880209.2019.1577465

Figure 1.

Figure 1.

Chang-wei-qing ameliorated colitis-associated tumour development in mouse model. (A) Tumour incidence. (B) Length of colon. (C) Tumour number. (D) Tumour size. (E) Colitis severity scores. (F) Representative histopathological images. NT: none treated, control group; AOM/DSS: treated with AOM, DSS and PBS, colitis-associated cancer group; AOM/DSS/Bif: treated with AOM, DSS and Bifico; AOM/DSS/CWQL: treated with AOM, DSS and low dose Chang-wei-qing; AOM/DSS/CWQH: treated with AOM, DSS and high dose Chang-wei-qing. Data are means ± SD (n = 6 for each group). Experiments were repeated for three times. *p < 0.05, **p < 0.01 vs. AOM/DSS group.